BofA analyst Chi Fong raised the firm’s price target on Roivant Sciences (ROIV) to $16.50 from $12 and keeps a Neutral rating on the shares following positive Phase 3 results for brepocitinib in dermatomyositis. The data set the stage for brepo’s commercial launch in 2027, says the analyst, who cites the positive data as well as recent progress in lipid nanoparticle litigation for the firm’s higher target.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ROIV:
- TD Cowen initiates $23 price target for Roivant Sciences
- Roivant Sciences price target raised to $20 from $18 at Jefferies
- Roivant Sciences price target raised to $21 from $15 at Guggenheim
- Roivant Sciences price target raised to $20 from $16 at JPMorgan
- Roivant Sciences price target raised to $20 from $18 at H.C. Wainwright